Interest of PET-MRI in the Evaluation of the Response After Neoadjuvant Treatment of Locally Advanced Rectal Adenocarcinoma

Обзор

With 50 patients included, this trial would be the largest pilot study evaluating the value of MRI PET in locally advanced rectal cancer. On the other hand, it would be the only pilot study performing several MRI PET during neoadjuvant treatment. Presumably, the response assessed at the 2nd MRI PET (before cycle 4 or induction chemotherapy) would be predictive of the overall response at the end of neoadjuvant treatment. Then, it would be possible to predict precociously the tumor response.

Подробное описание

The management of localized rectal cancer is done in two phases. The first phase, medical, combines a possible first chemotherapy, followed by a concomitant chemoradiotherapy. The second phase, 6 to 8 weeks later, consists of surgery of the rectum.

Magnetic resonance imaging (MRI) of the pelvis allows staging of the tumor and its possible lymph node extensions. MRI can also be used to assess tumor response after the first phase of treatment and before surgery. But MRI of the pelvis is partially imperfect.

PET-MRI is an examination that combines MRI with an injection of \[18 F\]fluorodeoxyglucose (18F-FDG). It is known to be more sensitive in assessing tumor stage and lymph node extensions compared to MRI and more sensitive in assessing tumor response before surgery.

The aim of this study is to determine predictive parameters for response to the first phase of treatment by accurately identifying the characteristics of tumors that have responded or not to treatment with chemotherapy and chemoradiotherapy.

Вмешательства

• Другое PET-MRI
  Each patient will have a pre-treatment PET-MRI (PET-MRI 1) within 21 days before the start of treatment. Induction chemotherapy may be performed at another center than the investigating center. After 3 cycles of induction chemotherapy and before the 4th cycle, a second PET MRI (PET MRI 2) will be performed. In patients who have received less than 3 cycles of induction chemotherapy, this mid-therapy PET-MRI will not be performed. A 3rd PET-MRI will be performed prior to radiation therapy (PET-

Первичные конечные точки

• Description of the correlation between the PET-MRI changes after neo-adjuvant treatment and the histological response after surgery in terms of metabolic criteria. [Срок оценки: At the surgery]
• Description of the correlation between the PET-MRI changes after neo-adjuvant treatment and the histological response after surgery in terms of MRI criteria. [Срок оценки: At the surgery]
• Description of the correlation between the PET-MRI changes after neo-adjuvant treatment and the histological response after surgery in terms of anatomopathological criteria. [Срок оценки: At the surgery]

Вторичные конечные точки (12)

• Comparison of the first PET-MRI staging with standard of care imaging, namely pelvic MRI in terms of tumor volumes [Срок оценки: At the PET MRI pretherapy (= PET MRI 1)]
• Comparison of the first PET-MRI staging with standard of care imaging, namely pelvic MRI in terms of SUVmax values [Срок оценки: At the PET MRI pretherapy (= PET MRI 1)]
• Comparison of the first PET-MRI staging with standard of care imaging, namely pelvic MRI in terms of ADC values [Срок оценки: At the PET MRI pretherapy (= PET MRI 1)]
• Description of the specific PET-MRI responses at mid-treatment of the neoadjuvant chemotherapy in terms of delta tumor volume [Срок оценки: At the 2nd PET (PET2), up to 28 months]
• Description of the specific PET-MRI responses at mid-treatment of the neoadjuvant chemotherapy in terms of delta SUVmax values [Срок оценки: At the 2nd PET (PET2), up to 28 months]
• Description of the specific PET-MRI responses at mid-treatment of the neoadjuvant chemotherapy in terms of delta ADC values [Срок оценки: At the 2nd PET (PET2), up to 28 months]
• Description of the specific PET-MRI responses to neoadjuvant chemotherapy in terms of delta tumor volume [Срок оценки: At the 3rd PET (PET3), up to 28 months]
• Description of the specific PET-MRI responses to neoadjuvant chemotherapy in terms of delta SUVmax values [Срок оценки: At the 3rd PET (PET3), up to 28 months]
• Description of the specific PET-MRI responses to neoadjuvant chemotherapy in terms of delta ADC values [Срок оценки: At the 3rd PET (PET3), up to 28 months]
• Description of the specific PET-MRI responses to neoadjuvant radiochemotherapy in terms of delta tumor volume [Срок оценки: At the 4th PET (PET4), up to 28 months]
• Description of the specific PET-MRI responses to neoadjuvant radiochemotherapy in terms of delta SUVmax values [Срок оценки: At the 4th PET (PET4), up to 28 months]
• Description of the specific PET-MRI responses to neoadjuvant radiochemotherapy in terms of delta ADC values [Срок оценки: At the 4th PET (PET4), up to 28 months]

Критерии участия

Критерии включения

• World Health Organization (WHO)/Eastern Cooperative Oncology Group (ECOG) 0 to 2
• Histologically proven rectal cancer
• clinical tumor classification (cT) : cT3 - cT4 or all T / N+ / M0
• Tumor resectable or considered resectable after chemoradiotherapy
• Decision chemotherapy followed by neoadjuvant chemoradiotherapy decided at the organ Multidisciplinary Meeting
• Absence of distant metastases
• Adequate contraception for women of childbearing potential
• Free, signed and informed consent
• For women of childbearing potential : negative pregnancy test

Критерии исключения

• Subject with Uncontrolled diabetes
• Contraindication to surgery
• Contraindication to MRI
• Contraindication to PET scan
• Contraindication to chemotherapy
• History of pelvic radiotherapy
• History of major co-morbidity that may prevent treatment and no active infection (HIV or chronic hepatitis B or C)
• Colloid (mucinous) adenocarcinoma
• Presence of distant metastases
• Contraindication to 5-FluoroUracil (FU), oxaliplatin or irinotecan
• History of known Gilbert's disease
• Patient with known UGT1A1 genotype
• Known Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency
• Medical history of chronic diarrhea or inflammatory disease of the colon or rectum
• Medical history of angina or myocardial infarction.
• Active progressive infection or any other serious medical condition that could compromise the administration of the treatment
• Other concurrent cancer, or medical history of cancer other than treated in situ cervical carcinoma or basal cell carcinoma or squamous cell carcinoma
• Patient enrolled in another clinical trial testing an investigational agent
• Pregnant or breastfeeding woman
• Persons deprived of their freedom or under guardianship or incapable of giving consent
• Any psychological, familial, sociological or geographic condition that may interfere with the study protocol or follow-up schedule

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Модель наблюдения

Только случаи

Центры проведения

Франция · 1 центр

• Institut de cancérologie Strasbourg Europe — Strasbourg

Идентификаторы

NCT: NCT05772481 · 2022-007

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗